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Abstract
Background: The translocation t(11;18)(q21;q21) is the most frequent chromosomal aberration associated with MALT
lymphoma and results in constitutive NF-kB activity via the expression of an API2-MALT1 fusion protein. The properties of
the reciprocal MALT1-API2 were never investigated as it was reported to be rarely transcribed.
Principal Findings: Our data indicate the presence of MALT1-API2 transcripts in the majority of t(11;18)(q21;q21)-positive
MALT lymphomas. Based on the breakpoints in the MALT1 and API2 gene, the MALT1-API2 protein contains the death
domain and one or both immunoglobulin-like domains of MALT1 (,90% of cases) - mediating the possible interaction with
BCL10 - fused to the RING domain of API2. Here we show that this RING domain enables MALT1-API2 to function as an E3
ubiquitin ligase for BCL10, inducing its ubiquitination and proteasomal degradation in vitro. Expression of MALT1-API2
transcripts in t(11;18)(q21;q21)-positive MALT lymphomas was however not associated with a reduction of BCL10 protein
levels.
Conclusion: As we observed MALT1-API2 to be an efficient target of its own E3 ubiquitin ligase activity, our data suggest
that this inherent instability of MALT1-API2 prevents its accumulation and renders a potential effect on MALT lymphoma
development via destabilization of BCL10 unlikely.
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Introduction
Extranodal marginal zone B-cell lymphoma of mucosa-associated
lymphoid tissue (MALT), or MALT lymphoma, represents 7–8% of
all B-cell lymphomas. Two translocations specifically associated with
MALT lymphoma are t(1;14)(p22;q32) and t(14;18)(q32;q21), which
upregulate the expression of the BCL10 [1,2] and the MALT1 [3,4]
gene, respectively, via their fusion to the IgH enhancer. The most
important translocation, present in ,40% of pulmonary and ,10–
30% of gastric MALT lymphomas, is t(11;18)(q21;q21), which
rearranges the API2 and the MALT1 gene [5,6]. In approximately
half of the cases, the resulting API2-MALT1 fusion protein contains
the three N-terminal baculovirus IAP repeat (BIR) domains of API2
fused to the C-terminal caspase-like domain of MALT1. Depending
on the breakpoint in the MALT1 gene however, the fusion protein
cancontaininadditiononeortwoimmunoglobulin(Ig)-likedomains
of MALT1, as observed in ,40% and ,10% of the cases,
respectively (Fig 1A) [7].
API2 belongs to the inhibitor of apoptosis protein (IAP) family
and has been implicated in anti-apoptotic processes, with an
important role for its BIR domains as ‘protein sink’ for apoptosis
mediators like caspase-3 and -7 [8]. In addition, a C-terminal
really interesting new gene (RING) domain confers API2 with an
E3 ubiquitin ligase activity [9], and ubiquitination-induced
degradation of pro-apoptotic proteins like SMAC/DIABLO [10]
might contribute significantly to its anti-apoptotic function.
MALT1 [11,12] and BCL10 [13] on the other hand are
important players in the signalling cascade from the antigen
receptors on B- and T-cells to the transcription factor NF-kB.
Upon T-cell receptor (TCR) triggering, CARMA1 recruits the
BCL10-MALT1-TRAF6 complex to the lipid rafts surrounding
the receptor [14–17]. Raft-mediated oligomerization activates the
E3 ubiquitin ligase activity of TRAF6, resulting in Lys63-linked
polyubiquitination of MALT1 [18] and BCL10 [19]. This
mediates the recruitment of the IKKa/IKKb/IKKc complex to
the CARMA1-BCL10-MALT1 complex [18,19] and induces full
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4822Figure 1. RT-PCR analysis of MALT1-API2 expression in t(11;18)(q21;q21)-positive MALT lymphoma. A, Features of MALT1, API2, and the
fusion proteins API2-MALT1 and MALT1-API2. Indicated is the domain content (solid bars) of the API2-MALT1 fusion variants A7M3, A7M5, A7M8 and
A7M9 (fusion API2 exon 7 to MALT1 exon 3/5/8/9, respectively) and their corresponding MALT1-API2 fusion variants M2A8, M4A8, M7A8 and M8A8
(fusion MALT1 exon 2/4/7/8, respectively, to API2 exon 8). B, Shown are the amplification products of nested PCR reactions on cDNA extracted from
14 t(11;18)(q21;q21)-positive MALT lymphoma cases (see Table 1). A PCR on pcD-F-M2A8, pcD-F-M4A8 and/or pcD-F-M8A8 was performed as positive
control, as indicated. An RT-PCR for MALT1 and GAPDH was included for RNA quality control. C, Results of quantitative RT-PCR for cases 11 and 12 for
MALT1-API2, API2-MALT1 and HPRT1. For primers used, see Materials and Methods and Table 2.
doi:10.1371/journal.pone.0004822.g001
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the Lys63-linked polyubiquitination of IKKc [20]. The important
function of MALT1 and BCL10 in antigen receptor signalling to
NF-kB suggests a role for enhanced NF-kB activation in MALT
lymphoma development.
Also API2-MALT1 has been linked to constitutive NF-kB
activation [21,22] via polyubiquitination of IKKc [23,24]. The
permanent association of the fusion protein with the lipid rafts
[24,25] or its oligomerization [23] via the first BIR domain
bypasses the normal requirement of BCL10-mediated oligomer-
ization of the MALT1-TRAF6 complex, resulting in TRAF6-
mediated NF-kB activation without the need for antigen receptor
triggering [26]. NF-kB activation by API2-MALT1 has been
shown to upregulate anti-apoptotic genes [25,27]. In addition,
API2-MALT1 retains the ability of API2 to interact with SMAC/
DIABLO [28], suggesting that API2-MALT1 also interferes
indirectly with apoptotic signalling. In contrast to API2 however,
API2-MALT1 has no E3 ubiquitin ligase activity and cannot
ubiquitinate and target BCL10 for proteasomal degradation [29].
This could explain the increased BCL10 expression levels in
MALT lymphomas with t(11;18)(q21;q21) [29], which, together
with the unusual nuclear localization of BCL10 in these
lymphomas [30,31] have been suggested to contribute to the
oncogenic character of this translocation. Altogether, these data
point to divergent roles for API2-MALT1 in MALT lymphoma-
genesis.
In contrast to API2-MALT1, the reciprocal fusion MALT1-API2
produced on the der(18) of the t(11;18)(q21;q21) escaped attention as
initial reports found MALT1-API2 RNA not to be consistently
expressed [32–34].Analyses of the genomic breakpoints showed that
although the translocation is accompanied by deletions, duplications
and insertions, a MALT1-API2 fusion protein can be formed in the
majority of cases [35,36]. This raised the question whether the
reciprocal fusion protein might hinder MALT lymphomagenesis
and induce its own transcriptional silencing.
MALT1-API2 always contains the N-terminal death domain
(DD) of MALT1 fused to the C-terminal RING domain of API2.
Variability of the breakpoints in MALT1 generates MALT1-API2
fusion variants that can contain in addition one or two Ig-like
domains of MALT1 (Fig 1A) [35,36]. We recently showed that the
DD and Ig-like domains of MALT1 cooperate for BCL10 binding,
whereas two functional TRAF6 binding sites in MALT1, the first
one directly 39 of the second Ig-like domain (T6-Ig) and the second
in the MALT1 C-terminus (T6-C), are involved in TRAF6
recruitment [26]. The presence of these BCL10 and TRAF6
binding sites in some of the MALT1-API2 fusion variants in
combination with the RING E3 ubiquitin ligase domain of API2
suggests that these MALT1-API2 proteins could bind BCL10
and/or TRAF6 and mark them for ubiquitination-induced
degradation.
In this study we provide evidence that MALT1-API2 expression
is not generally silenced in t(11;18)(q21;q21)-positive MALT
lymphomas. We furthermore show that the MALT1-API2 fusion
variants with one or both Ig-like domains of MALT1 do bind
BCL10 though fail to interact with TRAF6. The RING domain in
addition provides MALT1-API2 with an E3 ubiquitin ligase
activity, allowing the MALT1-API2 variant with one Ig-like
domain to trigger ubiquitination and proteasome-mediated
degradation of BCL10 in vitro. However, the RING domain also
destabilizes MALT1-API2 itself via auto-ubiquitination-induced
degradation. This inherent instability of MALT1-API2 most likely
limits its protein level in t(11;18)(q21;q21)-positive MALT
lymphomas and thus renders a possible effect on their develop-
ment via destabilization of BCL10 unlikely.
Results
MALT1-API2 expression in MALT lymphoma with
t(11;18)(q21;q21)
Although initial reports found MALT1-API2 not to be expressed
in the t(11;18)(q21;q21)-positive MALT lymphoma cases analyzed,
no correlation was made with the genomic architecture at the
breakpoint on the der(18) chromosome in these cases [32–34]. We
therefore analyzed via RT-PCR expression of MALT1-API2 in 14
cases of t(11;18)(q21;q21)-positive MALT lymphoma, of which the
fusion junctions on der(18) had previously been characterized at
the genomic level in 10 of these cases (Table 1) [35,36]. MALT1-
API2 transcripts were identified in 8 out of the 14 cases (case 1–14,
Fig 1B, Fig S1AB, Table 1). Sequencing of the PCR products was
performed to identify the MALT1-API2 fusion variant and
confirmed the generation of in-frame fusions in all cases. In the
6 cases for which no MALT1-API2 fusion could be detected via
RT-PCR, one case (case 7) did not reveal a MALT1-API2 fusion at
the genomic level either [36], while for 4 other cases (case 2, 3, 13
and 14), the absence of MALT1-API2 transcripts most likely
reflects poor RNA quality as also no MALT1 transcript could be
amplified (Fig 1B). In total, for 7 of the 9 cases for which previously
a MALT1-API2 fusion was demonstrated at the genomic level, the
MALT1-API2 variant could be confirmed at the transcript level
(Table 1).
Quantitative RT-PCR furthermore showed that although
MALT1-API2 is much lower expressed than API2-MALT1, its
expression level is still about half that of HPRT1 and thus of
potential biological significance (Fig 1C). The high expression level
of API2-MALT1 reflects its potential to upregulate its own
expression via activation of NF-kB, which drives transcription
from the API2 promoter [37].
In conclusion, these data argue against silencing of MALT1-
API2 transcription in t(11;18)(q21;q21)-positive MALT lympho-
mas.
BCL10 but not TRAF6 interacts with Ig-like domain-
containing MALT1-API2 variants
MALT1 requires its DD and Ig-like domains to bind BCL10,
while TRAF6 is recruited to TRAF6 binding sites in the second Ig-
like domain (T6-Ig) and the C-terminus (T6-C) of MALT1 (Fig 1A)
[26]. To examine whether MALT1-API2 also recruits BCL10
and/or TRAF6, we transiently expressed the different MALT1-
API2 fusion variants fused to a biotinylation (bio) tag together with
the E. coli BirA biotin protein ligase in HEK-293T cells. Protein
complexes of biotinylated MALT1-API2 were subsequently
pulled-down with streptavidin-coated paramagnetic beads, as
recently described [38]. While M2A8 (Fig 1A, fusion of exon 2
of MALT1 to exon 8 of API2) did not bind BCL10, the inclusion of
one or two Ig-like domains of MALT1 in the MALT1-API2 fusion
variants M4A8 and M7A8/M8A8, respectively (Fig 1A, fusion of
exon 4, 7 and 8 of MALT1, respectively, to exon 8 of API2)
resulted in co-precipitation of endogenous BCL10, similarly as for
MALT1 (Fig 2A). In contrast, the presence of the TRAF6 binding
site T6-Ig of MALT1 in M7A8 and M8A8 did not allow the
recruitment of endogenous TRAF6, while TRAF6 efficiently co-
precipitated with MALT1 (Fig 2A). To exclude cell-type specific
interactions, we generated SSK41 Marginal Zone lymphoma B-
cells stably expressing the BirA biotin ligase together with the bio-
tagged M4A8 fusion variant. Streptavidin-mediated pull-down
again showed an efficient co-purification of endogenous BCL10
with M4A8, despite its lower expression level in SSK41 compared
to HEK-293T cells (Fig 2B).
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with one or two Ig-like domains of MALT1 in MALT1-API2
facilitates the interaction with BCL10, but not with TRAF6.
M4A8 ubiquitinates BCL10 via its RING domain
The RING domain of API2 enables it to function as an E3
ubiquitin ligase, capable of auto-ubiquitination [9,39] and
ubiquitination of interacting proteins [10,40–42], like BCL10 via
its interaction with the first BIR domain of API2 [29]. We thus
wondered whether also MALT1-API2 possessed E3 ubiquitin
ligase activity. The different bio-tagged MALT1-API2 fusion
variants were therefore transiently expressed in HEK-293T cells
together with HA-tagged ubiquitin (Ub) and subsequently purified
via streptavidin-mediated pull-down. Western blot analysis with a-
Flag (for API2 and MALT-API2) and a-HA (for HA-Ub) clearly
showed that all MALT1-API2 fusion variants were ubiquitinated,
similarly as API2 (Fig 3A). Furthermore, mutation of the critical
His and the two flanking Cys residues of the RING domain
(RING mutant; RM) abolished most ubiquitination (Fig 3A),
indicating auto-ubiquitination of MALT1-API2. Interestingly,
cellular BCL10 co-purified with bio-tagged M4A8, and to a much
lesser extent with M7A8, showed a similar pattern of ubiquitina-
tion, which again was completely dependent on a functional
RING domain in MALT1-API2 (Fig 3A). Remarkably, we were
not able to co-precipitate BCL10 together with bio-tagged full-
length API2 (Fig 3A), in contrast to a recent report on the BIR-
mediated interaction of BCL10 with API2 [29]. To exclude that
the slower migrating BCL10 bands observed in Fig 3A resulted
from BCL10 phosphorylation, protein complexes co-purified with
bio-tagged wild-type (WT) M4A8 were treated with l-PPase, but
this did not affect the migration pattern of BCL10 (Fig 3B).
To further investigate these BCL10 modifications by M4A8, we
transiently expressed HA-bio-tagged BCL10 in HEK-293T cells,
alone or in combination with Flag-tagged WT- or RM-M4A8.
While no effect of the RING mutant M4A8 on BCL10 was seen in
the cell lysate, co-expression of BCL10 with wild-type M4A8 again
induced BCL10 modifications (indicated with asterisks, a-BCL10
and a-HA panel Fig 3C). When the cells were treated with the
Table 1. Characteristics of the MALT lymphoma cases examined.
case
no. previous no. site of tumour
API2-MALT1 variant at
transcript level
(3)
MALT1-API2 variant at
genomic level
(3) RT-PCR+sequencing
BCL10 nuclear
expression
1 case 2
(1) stomach A7M5 M4A8 M4A8 +
2 stomach A7M8 na 2 +
3 case 3
(1) stomach A7M5 M4A8 2 na
4 stomach A7M9 na M8A8 +
5 case 18
(1) small intestine A7M9 M8A8 M8A8 +
6 case 8
(1) lung A7M5 M4A8 M4A8 +
7 case 16
(1) stomach A7M8 22 +
8 case 17
(1) stomach A7M8 M4A8 2 +
9 case 10
(1) stomach A7M5 M4A9 M4A9 +
10 case 5
(1) stomach A7M5 M4A8 M4A8 +
11 case 5
(2) stomach A7M9 M8A8 M8A8 na
12 case 3
(2) stomach A7M5 M4A8 M4A8 na
13 stomach A7M8 na 2 na
14 spleen A7M5 na 2 na
15 stomach A7M8 na 2 na
(1)case number in [36] data not shown for case 15.
(2)case number in [35].
(3)data published in [35,36].
na=not analyzed.
2=not found.
doi:10.1371/journal.pone.0004822.t001
Figure 2. MALT1-API2 interacts with BCL10 via the MALT1 Ig-
like domains. A, Inclusion of one or two Ig-like domains of MALT1 in
MALT1-API2 allows the binding of endogenous BCL10 in HEK-293T.
Immunoblot with a-TRAF6, a-BCL10 and a-Flag on protein complexes
co-precipitated with Flag-bio-tagged M2A8, M4A8, M7A8, M8A8 and
MALT1, transiently expressed in HEK-293T cells. B, M4A8 binds
endogenous BCL10 in SSK41 B-cells. Immunoblot with a-BCL10 and
a-Flag on protein complexes pulled down with Flag-bio-tagged M4A8
stably expressed in SSK41-BirA B-cells. Precipitated protein complexes
from two different SSK41-BirA-M4A8 clones (69 and 93) were compared
to the protein complex from HEK-293T cells with transient overexpres-
sion of M4A8. Molecular weight standards are in kDa.
doi:10.1371/journal.pone.0004822.g002
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PLoS ONE | www.plosone.org 4 March 2009 | Volume 4 | Issue 3 | e4822Figure 3. BCL10 is a target of the RING E3 ubiquitin ligase activity of MALT1-API2 variants with MALT1 Ig-like domains. A–B, Flag-
bio-tagged M2A8, M4A8 and M7A8 (wild-type (WT) or RING mutant (RM)), API2 and empty vector were transiently expressed together with HA-Ub in
HEK-293T. Protein complexes were precipitated with streptavidin-coated paramagnetic beads and analyzed with a-Flag, a-HA (after stripping of a-
Flag) and a-BCL10. A, Mono- and di-ubiquitinated bands of WT MALT1-API2 and API2 are indicated with asterisks in the a-Flag and a-HA panel. B,
Where indicated, the precipitated protein complex was treated with l-PPase to remove phosphorylation. C–D, BCL10 ubiquitination by M4A8
becomes more pronounced after inhibition of the proteasome. HA-bio-tagged BCL10 was transiently overexpressed in HEK-293T together with Flag-
tagged M4A8 (WT or RM) or empty vector. Where indicated, cells were pretreated with MG132 to inhibit to proteasome. C, Cell lysates were
immunodetected with a-BCL10 and a-HA (both for HA-BCL10), a-Flag and a-b-actin. BCL10 ubiquitination is indicated with asterisks. D, Following
denaturation of the cell lysates, HA-bio-tagged BCL10 was precipitated via streptavidin pull-down and where indicated, treated with l-PPase to
remove phosphorylation. The bio-IPs were then immunodetected with a-BCL10, a-Flag (to check if the denaturation was complete) and a-Ub. BCL10
ubiquitination is indicated with asterisks. Molecular weight standards are in kDa.
doi:10.1371/journal.pone.0004822.g003
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modifications became more pronounced, further suggesting that
M4A8 induces BCL10 ubiquitination (Fig 3C). This was even
more obvious when BCL10 was purified via streptavidin pull-
down in denaturing conditions to destroy existing protein
interactions (a-BCL10 panel Fig 3D, left part). Again, phosphor-
ylation could be excluded, since treatment of the purified BCL10
proteins with l-PPase did not affect the slower migrating BCL10
bands (Fig 3D, right part). In contrast, these bands could be
revealed with an a-Ub antibody (Fig 3D).
Altogether, these data indicate that MALT1-API2 can function
as an E3 ubiquitin ligase via the RING domain of API2. While all
fusion variants auto-ubiquitinate, only M4A8 is able to induce
significant BCL10 ubiquitination in overexpression experiments.
Ubiquitination of BCL10 by M4A8 induces its degradation
by the proteasome
The RING domains of IAPs are involved in ubiquitination-
mediated protein degradation [10,29,39–42]. As we consistently
observed a lower expression level for the wild-type MALT1-API2
proteins compared to their RING mutants (Fig 4B) even though
more DNA was used for transfection (see Materials and Methods),
we expected that also MALT1-API2 targets proteins for
degradation. As shown in Fig 4A, expression of M4A8 in HEK-
293T indeed reduced the BCL10 protein level. A smaller effect
was seen for M7A8, while M2A8 did not affect the BCL10 level.
Like its polyubiquitination, also the reduction of BCL10 levels by
M4A8 and M7A8 was dependent on a functional RING domain,
as the RING mutant (RM) had no effect (Fig 4BC). In contrast to
M4A8 and M7A8, expression of wild-type API2 did not affect
BCL10 protein levels, like its RING mutant (Fig 4B), which is in
agreement with our observation that BCL10 does not interact with
API2 in HEK-293T (Fig 3A). Similarly, none of the MALT1-API2
fusion variants had an effect on the TRAF6 protein level (Fig 4A),
conform the absence of TRAF6 in MALT1-API2 protein
complexes (Fig 2A).
To determine whether BCL10 degradation occurred via the
proteasome or the lysosome, we tested the effect of inhibitors on
BCL10 protein levels in HEK-293T cells expressing M4A8.
Pretreatment of HEK-293T with MG132 prevented BCL10
degradation, even though the M4A8 level increased at the same
time (Fig 4D). The same result was obtained when cells were
pretreated with the more specific proteasomal inhibitor lactacystin
(Fig 4E), while BCL10 degradation upon M4A8 expression could
not be blocked with NH4Cl, an inhibitor of the lysosome (Fig 4F).
Altogether, these data indicate that the RING domain of M4A8
induces proteasome-mediated degradation of BCL10.
Expression of MALT1-API2 does not affect the BCL10
protein level and nuclear localization in
t(11;18)(q21;q21)-positive MALT lymphoma
To assess whether expression of MALT1-API2 also affects
BCL10 protein levels in vivo, we performed western blot analysis to
evaluate BCL10 protein levels in t(11;18)(q21;q21)-positive MALT
lymphoma samples with or without MALT1-API2 expression.
Expression of M8A8 (case 4 and 5) was associated with reduced
BCL10 levels when compared to two cases without the reciprocal
MALT1-API2 (case 7 and 8, Fig 5A). Analysis of an additional case
however showed no effect of M8A8 expression (case 11), although
BCL10 expression was strongly upregulated compared to
t(11;18)(q21;q21)-negative MALT lymphoma cases, control spleen
or lymph node (Fig 5B). In contrast, two of the three samples with
the M4A8/9 variant, which induced the highest levels of BCL10
ubiquitination and degradation in HEK-293T cells, showed an
increase in BCL10 expression levels (case 9 and 10), whereas a
small reduction was observed in the remaining case (case 1,
Fig 5A). Furthermore, immunohistochemistry showed a nuclear
localization of BCL10 for all cases examined, with no differences
between cases without (case 2, 7 and 8) or with expression of
M4A8/9 (case 1,6, 9 and 10) or M8A8 (case 4 and 5) (Table 1; data
not shown).
In conclusion, these data do not suggest an effect of MALT1-
API2 expression on BCL10 protein levels and nuclear staining in
these MALT lymphomas.
MALT1-API2 reduces NF-kB activation by API2-MALT1
Finally, the effect of MALT1-API2 expression on API2-
MALT1-mediated NF-kB activation was examined by co-
expression of the different API2-MALT1 fusion variants A7M3/
A7M5/A7M8 in combination with their corresponding WT or
RM MALT1-API2 variant M2A8/M4A8/M7A8 in HEK-293T.
As shown in Fig 6, all MALT1-API2 fusion variants reduced NF-
kB activation by API2-MALT1 to a similar extent. Although this
was partly associated with an intact RING domain in MALT1-
API2, MALT1-API2 also significantly affected NF-kB signalling
independently of its E3 ubiquitin ligase activity.
Discussion
The translocation t(11;18)(q21;q21) is a frequent genomic
aberration associated with B-cell MALT lymphoma. Nowadays,
it is generally accepted that the API2-MALT1 fusion protein
expressed from the der(11) contributes to B-cell transformation
and progression of MALT lymphomas via constitutive NF-kB
activation. In contrast, not much is known about the reciprocal
MALT1-API2 fusion generated on the der(18) chromosome.
Although it was initially reported that MALT1-API2 is not
consistently transcribed, we show here that the majority of MALT
lymphomas with t(11;18)(q21;q21) do express in-frame MALT1-
API2 transcripts. Our data furthermore show that the RING
domain of API2 provides MALT1-API2 with an E3 ubiquitin
ligase activity. In addition, the inclusion of at least one Ig-like
domain of MALT1 in MALT1-API2 results in the binding and
ubiquitination of BCL10, which triggers its degradation by the
proteasome in vitro. However, no correlation was found between
the presence of a MALT1-API2 transcript and the BCL10
expression level and nuclear staining in MALT lymphoma
samples, most likely due to the efficient downregulation of
MALT1-API2 protein levels via auto-ubiquitination.
Initial reports could not detect expression of MALT1-API2 in
the t(11;18)(q21;q21)-positive MALT lymphoma cases examined
[32–34]. It is possible that the t(11;18)(q21;q21) is accompanied by
deletions or other genomic aberrations that obstruct the
generation of a MALT1-API2 fusion on der(18). One group
indeed reported deletions 59 of the breakpoint on der(18) in all
three MALT lymphoma cases examined [32]. Similarly, while
only small intronic deletions were detected in the API2 and/or the
MALT1 gene in three t(11;18)(q21;q21)-positive MALT lymphoma
cases with expression of MALT1-API2, the failure to amplify a
MALT1-API2 transcript in two other cases correlated with a
deletion of a substantial part of 39-API2 on der(18) ([35] and
Baens, unpublished results). Such deletion involving the N-
terminal part of the MALT1 gene or the C-terminal part of the
API2 gene is however not a general observation in MALT
lymphomas with t(11;18)(q21;q21), as a more recent genomic
characterization of 19 t(11;18)(q21;q21)-positive MALT lympho-
mas demonstrated in 13 cases the generation of a genomic
MALT1-API2 in MALT Lymphoma
PLoS ONE | www.plosone.org 6 March 2009 | Volume 4 | Issue 3 | e4822Figure 4. M4A8 induces BCL10 degradation by the proteasome. A, M4A8, and to a lesser extent M7A8, induces BCL10 degradation. Cell
lysates of HEK-293T cells, transiently transfected with empty vector or increasing concentrations of Flag-tagged M2A8, M4A8 and M7A8 were
immunodetected with a-Flag, a-BCL10, a-TRAF6 and a-b-actin. The BCL10 protein level (%) is compared to empty vector-transfected cells after
normalization to b-actin. B, M4A8 requires a functional RING domain to induce BCL10 degradation. HEK-293T cells, transiently transfected with empty
vector or Flag-tagged M2A8, M4A8, M7A8 and API2 (WT or RM) were lysed and immunodetected with a-Flag, a-BCL10 and a-b-actin. The BCL10
protein level (%) is compared to empty vector-transfected cells after normalization to b-actin and represents the mean of three independent
experiments, with indicated standard deviation. C, HEK-293T cells were transiently transfected with empty vector or increasing concentrations of
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duplications and/or insertions. Only in the 6 cases for which the
amplification failed, deletions involving the entire C-terminal API2
and/or the entire N-terminal MALT1 gene were expected [36]. To
address this apparent discrepancy between the presence of
MALT1-API2 fusions at the genomic level and the absence of
MALT1-API2 transcripts, we analyzed in this study MALT1-API2
expression in 14 t(11;18)(q21;q21)-positive MALT lymphoma
cases, of which 9 cases were previously reported to contain a
MALT1-API2 fusion at the genomic level. Surprisingly, RT-PCR
and sequencing confirmed the expression of MALT1-API2 in 7 out
of these 9 cases (Table 1), which clearly shows that transcriptional
silencing of MALT1-API2 is not a general phenomenon in
t(11;18)(q21;q21)-positive MALT lymphomas.
Based on the breakpoints in the API2 and MALT1 gene, a
number of API2-MALT1 fusion variants have been described [7].
For all these variants, the anticipated reciprocal MALT1-API2
fusion protein always contains the N-terminal DD of MALT1 and
the C-terminal RING domain of API2. The majority of cases
however could contain in addition one or two Ig-like domains of
MALT1 (Fig 1A, the M4A8 and M7A8/M8A8 fusion variants), as
also demonstrated via genomic characterization of the der(18)
chromosome [35,36]. Here we show that the inclusion of at least
one Ig-like domain mediates the binding of MALT1-API2 to
BCL10, conform our previous observation that the DD and the Ig-
like domains of MALT1 cooperate for BCL10 binding [26]. In
contrast, TRAF6 did not interact with any of the fusion variants,
despite the presence of the TRAF6 binding site associated with the
second Ig-like domain (T6-Ig) of MALT1 in M7A8 and M8A8.
This probably reflects conformational constraints imposed by the
C-terminal domains of API2, as full-length MALT1 efficiently
interacted with endogenous TRAF6 [26], or indicates the necessity
of C-terminal sequences of MALT1 for efficient binding of
TRAF6 to this site. In favour of the latter is our observation that
deletion of the C-terminus of MALT1 in the API2-MALT1 fusion
variant A7M3 also abolished TRAF6 binding to the T6-Ig site
[26].
RING domains are able to catalyze the transfer of ubiquitin to a
substrate. Our data show that the RING domain of API2 also
enables MALT1-API2 to function as an E3 ubiquitin ligase
capable of auto-ubiquitination, similarly as API2. Indeed, API2 is
a known E3 protein involved in the ubiquitination-induced
degradation of itself [9,39] and of interacting proteins like RIP1
[40], TRAF1 [41] and SMAC [10]. Also BCL10 has recently been
reported to be a target of API2-induced ubiquitination and
degradation via binding to the BIR1 domain of API2 [29]. In this
study, we were however unable to detect an interaction between
API2 and endogenous BCL10, nor did we observe a RING-
dependent effect of API2 overexpression on BCL10 stability.
Although this confirms our previous observation that endogenous
BCL10 does not interact with the BIR domains of API2 in API2-
MALT1 [26], it needs to be determined whether the use of
different cell types underlies this discrepancy or whether the
interaction of BCL10 with API2 is stimulus-dependent [29,43].
Nevertheless, we did detect a RING domain-dependent ubiqui-
tination of BCL10 by M4A8, resulting in the degradation of
BCL10 by the proteasome. Furthermore, while the inclusion of the
second Ig-like domain of MALT1 in M7A8 somewhat increased
its capacity to bind BCL10, this fusion variant could only modestly
induce BCL10 ubiquitination and degradation, again suggesting
conformational constraints.
Given the importance of NF-kB activation to the oncogenic
behaviour of API2-MALT1 [27], the effect of MALT1-API2
expression on API2-MALT1-mediated NF-kB activation was
examined in vitro. Interestingly, all MALT1-API2 fusion variants
Figure 5. Expression of MALT1-API2 does not affect the BCL10
protein level in t(11;18)(q21;q21)-positive MALT lymphoma. A,
Lysates of 7 MALT lymphoma samples were immunodetected with a-
MALT1-C, a-BCL10 and a-b-actin to evaluate the BCL10 protein level.
Specifications about API2-MALT1 and MALT1-API2 transcript variants
(from Table 1) are indicated. The BCL10 and MALT1 protein level (%) is
compared to case 7 after normalization to b-actin. Different parts of the
same blot were combined as indicated via the dotted lines. B,
Immunoblot with a-BCL10 and a-b-actin on lysates from 4 MALT
lymphoma cases (with specifications as indicated) and control spleen
and lymph node samples. Different parts of the same blot were
combined as indicated via the dotted lines.
doi:10.1371/journal.pone.0004822.g005
Flag-tagged WT or RM M4A8. Cell lysates were analyzed with a-Flag, a-BCL10 and a-b-actin. The BCL10 protein level (%) is compared to empty vector-
transfected cells after normalization to b-actin. D–E, Proteasome inhibition reduces the degradation of BCL10 and of M4A8 itself. HEK-293T cells,
transiently transfected with empty vector or increasing concentrations of Flag-tagged M4A8 were pretreated with DMSO, MG132 (D) or lactacystin (E)
prior to harvesting. Cell lysates were analyzed with a-Flag, a-BCL10 and a-b-actin. F, Degradation of BCL10 or MALT1-API2 does not require the
lysosome. HEK-293T cells, transiently transfected with empty vector or increasing concentrations of Flag-tagged M4A8 were left untreated or
pretreated with NH4Cl prior to harvesting. Cell lysates were analyzed with a-Flag, a-BCL10, a-TRAF6 and a-b-actin.
doi:10.1371/journal.pone.0004822.g004
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partly via the presence of an intact RING domain. This can
however not be explained by the RING-mediated ubiquitination
and degradation of BCL10, as BCL10 is not required for NF-kB
activation by API2-MALT1 [26]. Further studies are thus needed
to investigate whether the RING E3 ubiquitin ligase activity of
MALT1-API2 affects specific proteins involved in API2-MALT1-
mediated signalling to NF-kB. Furthermore, these studies could
provide insight into the E3 ubiquitin ligase-independent mecha-
nism of MALT1-API2 to reduce NF-kB activation by API2-
MALT1. As this could possibly involve the DD of MALT1 and/or
the CARD (caspase recruitment domain) of API2, the identifica-
tion of interaction partners for these domains would form the
subject of interesting future research. Moreover, it remains to be
investigated whether expression of MALT1-API2 also reduces
API2-MALT1-mediated NF-kB activation in t(11;18)(q21;q21)-
positive MALT lymphomas, for example by analyzing its effect on
the Lys63-linked polyubiquitination of IKKc [23]. Unfortunately
we were unable to do so in this study due to insufficient MALT
lymphoma material available.
In addition to NF-kB activation by API2-MALT1, also the
increased BCL10 protein level [29] and the unusual nuclear
localization of BCL10 [30,31] have been suggested to contribute
to the oncogenic character of the t(11;18)(q21;q21) in MALT
lymphomas. The destabilizing effect of MALT1-API2 on BCL10 in
vitro thus suggests that MALT1-API2 could also interfere in this way
with the development of t(11;18)(q21;q21)-positive MALT lympho-
mas. However, the expression of MALT1-API2 did not affect the
nuclear staining of BCL10 in our MALT lymphoma cases analyzed.
In addition, we could not confirm decreased levels of BCL10 in
MALT lymphoma B-cells expressing M4A8, this in sharp contrast to
our in vitro observations. As MALT1-API2 is very unstable being an
efficient target of its own E3 ubiquitin ligase activity, this suggests
that its protein level in MALT lymphoma might be too low to affect
BCL10 stability and localization. Unfortunately, we were not able to
validate this further due to the lack of good quality antibodies able to
detect the MALT1-API2 protein.
In conclusion, our data show that the MALT1-API2 fusions with
one or both Ig-like domains of MALT1 can bind BCL10 and induce
its ubiquitination and proteasome-mediated degradation via the
RING domain of API2. However, MALT1-API2 is also an efficient
target of its own E3 ubiquitin ligase activity. This property of
MALT1-API2 most likely limits its protein level in t(11;18)(q21;q21)-
positive B-cells and makes a possible effect on MALT lymphoma
development via destabilization of BCL10 unlikely.
Materials and Methods
Constructs
Vectors enabling expression of biotinylated proteins (pcD-F-bio;
pcD-HA-bio) were constructed as described [26] and used to
generate constructs for MALT1, BCL10, API2, ubiquitin (Ub), the
MALT1-API2 fusion variants M2A8, M4A8, M7A8 and M8A8
(fusion of respectively exon 2, 4, 7 and 8 of MALT1 with exon 8 of
API2, Fig 1A) and their RING mutants (RM). PCR-based
mutagenesis was used to introduce the triple mutation of the Zinc
coordinating Histidine and the flanking Cysteines (C572S/
H574A/C578S) in the RING domain of API2, which was
subcloned in API2 and the MALT1-API2 constructs to create
the corresponding RM.
Cell culture, transfection and NF-kB reporter assays
Monoclonal SSK41 B-cell lines stably expressing Flag-tagged
BirA, alone or in combination with a Flag-bio-tagged M4A8, were
Figure 6. MALT1-API2 reduces NF-kB activation by API2-MALT1. NF-kB-dependent luciferase assay after co-expression of API2-MALT1
(A7M3/A7M5/A7M8) with its corresponding MALT1-API2 fusion variant (M2A8/M4A8/M7A8) in HEK-293T. NF-kB-dependent luciferase activity is
represented as fold induction of vector-transfected cells. Shown is one representative experiment of 2, performed in triplicate, with mean and
standard deviation. Lysates were immunodetected with a-Flag to confirm comparable API2-MALT1 expression in all cases.
doi:10.1371/journal.pone.0004822.g006
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cultured and transfected as described [26]. For transfections
involving MALT1-API2, a double amount of DNA of the wild-
type MALT1-API2 variants compared to their RING mutants was
used to obtain more equal expression levels. After 24 hours, cells
were harvested in 16PBS and lysed in a non-denaturing NDLB
lysis buffer, as described [26]. NF-kB reporter assays were
performed as described [26].
Inhibition of the lysosome and the proteasome
To inhibit the proteasome, cells were treated for 4 to 7 hours
with 50 mM MG132 (VWR International) or with 25 mM
lactacystin (Cayman, Bio-Connect, Huissen, The Netherlands)
prior to harvesting. DMSO treatment was included as a control.
To measure proteasome activity, 100 mg of cell lysate (20 mM
Tris-Cl pH 8.0, 0.5 mM EDTA, 0.035% SDS) was incubated with
200 mM Suc-LLVY-AFC (Sigma-Aldrich, Bornem, Belgium) for
30 min on 37uC, after which released AFC was quantified
(excitation 390 nm, emission 460 nm) using a FLUOstar Galaxy
Plate Reader (BMG Labtechnologies GmbH, Offenburg, Ger-
many). To inhibit the lysosome, cells were treated for 4 hours with
50 mM NH4Cl prior to harvesting.
Bio-IP and phosphatase treatment
The biotin-immunoprecipitation (bio-IP) method [38] was
performed as described [26]. Where indicated, cell lysates were
denatured in the presence of 1% SDS prior to bio-IP. To remove
phosphorylations following bio-IP, where indicated, beads were
resuspended in 16lambda protein phosphatase (l-PPase) reaction
buffer and treated with l-PPase (New England Biolabs, Westburg
BV, Leusden, The Netherlands).
SDS-PAGE and western blot analysis
SDS-PAGE and western blot analysis were performed as
described [26]. Antibodies used for immunodetection of the Flag
epitope (M2) and of b-actin (clone AC-15) were from Sigma-
Aldrich, of the HA epitope (12CA5) from Roche Diagnostics
Belgium (Vilvoorde, Belgium) and of BCL10 (sc-5273), TRAF6
(sc-7221) and Ub (sc-8017) from Santa Cruz Biotechnology (Tebu-
bio, Boechout, Belgium). Anti-MALT1-C is a rabbit polyclonal
antiserum raised against amino acids 731–824 of MALT1 [24].
The signal was visualized with the enhanced chemoluminescence
(ECL) system (Perkin Elmer, Zaventem, Belgium) and, where
indicated, quantified using the Advanced Image Data Analyzer
(AIDA) Software (Raytest BeNeLux B.V., Tilburg, The Nether-
lands). Where indicated, membranes were stripped (62.5 mM
Tris-Cl pH 6.7, 2% SDS and 100 mM b-mercaptoethanol) for
30 min at 60uC and, prior to reprobing, analyzed via western blot
detection with the appropriate secondary antibody to verify
complete stripping.
MALT lymphoma samples
Fifteen cases of t(11;18)(q21;q21)-positive MALT lymphoma
with fresh-frozen tumour tissues were collected, of which 10 (case 1
to 10) from the Department of Pathology, University of Cam-
bridge, UK and 5 (cases 11 to 15) from the Department of
Morphology and Molecular Pathology, University of Leuven,
Belgium (Table 1). t(11;18)(q21;q21) and the API2-MALT1 fusion
junction at the transcript level were identified previously (Table 1;
[35,36]; unpublished for cases 2, 4, 13–15). The breakpoint on the
der(18) was identified previously for 9 cases (Table 1; [35,36]).
Two t(11;18)(q21;q21)-negative MALT lymphoma cases and
control spleen and lymph node samples were retrieved from the
Department of Morphology and Molecular Pathology, University
of Leuven, Belgium. For western blot analysis, tumour tissues were
lysed in 100 mM Tris-Cl pH 8.0, 300 mM NaCl, 0.04% NaN3,
0.2% SDS, 2% NP-40, 1% Na-deoxycholate, 2 mM EDTA,
100 mg/ml PMSF and 1 mg/ml leupeptin. RNA isolation and
cDNA synthesis were performed as described ([30] for cases 1–10
and [35] for cases 11–14). BCL10 immunohistochemistry was
performed as described [30].
(Quantitative) RT-PCR and sequence analysis of MALT1-
API2 transcripts
To determine in our collection of t(11;18)(q21;q21)-positive
MALT lymphoma samples the MALT1-API2 fusion variant at
transcript level, two different RT-PCR reactions were performed:
one with primers MALT1-F1 (in MALT1 exon 2) and API2-R1 (in
RING domain of API2 exon 10), followed by a second round of
nested PCR with primers MALT1-F2 (in MALT1 exon 2) and
API2-R2 (in RING domain of API2 exon 10) (Fig 1B), and a
second one with primers MALT1-F3 (in MALT1 exon 4) and
API2-R1, followed by a nested PCR with primers MALT1-F4 (in
MALT1 exon 4) and API2-R2 (Fig S1AB). RT-PCR for MALT1
(with MALT1-F5 and MALT1-R1) and GAPDH (with GAPDH-F
and GAPDH-R) were performed to check for RNA quality. The
PCR products in Fig 1B were sequenced using primers MALT1-
F2 and API2-R2. Big Dye Terminator Cycle Sequencing
Reactions were analyzed on an ABI PRISM 3130 Genetic
Analyzer (Applied Biosystems, Lennik, Belgium). Quantitative
RT-PCR was performed with the LightCycler 480 SYBR Green I
master mix (Roche Diagnostics Belgium) and analyzed using the
comparative dCt method to check expression levels of HPRT1
(HPRT1-F/R), M8A8 (M8A8-F/R) and A7M9 (A7M9-F/R) for
case 11 and M4A8 (M4A8-F/R) and A7M5 (A7M5-F/R) for case
12. Primer sequences are shown in Table 2.
Table 2. Sequence of the primers used.
Primer Sequence Gene
MALT1-F1 59-TTGCCTAGACCTGGAGCAGT MALT1
MALT1-F2 59-GATTTCCTGCAGGCTATGGA MALT1
MALT1-F3 59-GCAGGCTTTTATGTCTGTCG MALT1
MALT1-F4 59-TTGAATTCAGCCAGTGGTCA MALT1
MALT1-F5 59-GTGGATTTGGAACACCAAGG MALT1
MALT1-R1 59-CCACTGTAGATTCCGCACAA MALT1
API2-R1 59-GAAGGAGCACAATCTTTGCAT API2
API2-R2 59-GGACACTTCTTTGTCCATACACAC API2
GAPDH-F 59-AATCCCATCACCATCTTCCA GAPDH
GAPDH-R 59-ACAGTCTTCTGGGTGGCAGT GAPDH
HPRT1-F 59-TGACACTGGCAAAACAATGCA HPRT1
HPRT1-R 59-GGTCCTTTTCACCAGCAAGCT HPRT1
M8A8-F 59-GCACTGAAGATGAATTAAATAATCTTGG MALT1
M8A8-R 59-TGGAATTACACAAGTCAAATGTTGAAA API2
A7M9-F 59-AGAAGATGAAATAAGGGAAGAGGAG MALT1
A7M9-R 59-TTCGCCAAAGGCTGGTC API2
M4A8-F 59-TCAGCCAGTGGTCACAG MALT1
M4A8-R 59-GCCATTCTATTCTTCCGGATTAATAATAAA API2
A7M5-F 59-GGAAGAGGAGAGAGAAAGAGC MALT1
A7M5-R 59-CAACTTGGATTCAGAGACGC API2
doi:10.1371/journal.pone.0004822.t002
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Figure S1 RT-PCR analysis of MALT1-API2 expression in
t(11;18)(q21;q21)-positive MALT lymphoma. A, Shown are the
amplification products of RT-PCR reactions with primers MALT1-
F3 and API2-R1 on cDNA extracted from 14 t(11;18)(q21;q21)-
positive MALT lymphoma cases (see Table 1). A PCR on pcD-F-
M4A8 and pcD-F-M8A8 was performed as positive control. B, A
second round of nested PCR was performed with primers MALT1-
F4 and API2-R2. For primer sequences, see Table 2.
Found at: doi:10.1371/journal.pone.0004822.s001 (1.63 MB PDF)
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